Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by it ...

Merck & Co., Inc. (NYSE:MRK) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 2:35 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President of Merck Research Laboratories Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Good afternoon, everybody. Thanks for joining us. Terence Flynn, US Biopharma Analyst at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.mor ...

会议主要讨论的核心内容 - 公司在过去3年多时间里,已经将Phase 3管线资产数量增加近3倍,达到21个独立资产 [5] - 公司未来5年内将推出的新药数量,将接近过去10年的总和,且大部分具有潜块头部市场的能力 [5][6] - 公司对短期和长期发展前景均保持信心,2023年全年收入预计将增长8%-10% [6] - 公司将继续通过内部研发和外部并购来丰富管线,保持科学驱动的策略,关注未满足的医疗需求和有价值的科学 [9][10] 问答环节重要的提问和回答 - 分析师询问公司是否还有进一步扩充管线的空间,以及在外部并购方面的策略 [7][8][10] - 公司表示会继续保持科学驱动的并购策略,关注未满足的医疗需求和有价值的科学,并表示未来仍有扩充管线的空间 [9][10] - 分析师询问公司在IRA政策影响下如何调整内部研发和外部并购策略,公司表示已将IRA政策影响纳入考虑,并表示仍有增长机会 [11][12][13] - 公司表示GARDASIL在中国市场仍有较大增长空间,正在采取多项措施提升渗透率,并有望获得男性适应症批准 [17][18] - 公司对WINREVAIR在美国和欧洲市场的发展前景表示乐观,并计划将其推广至中国市场 [34][35][36][37] - 公司表示正在开展TL1A在溃疡性结肠炎和克罕病适应症的III期临床试验,并对其疗效和安全性表示乐观 [41][42][43][45] - 公司对CAPVAXIVE在成人肺炎球菌疫苗市场的竞争地位表示信心,并表示有能力进一步提升疫苗覆盖率 [46][47]

GERMANY - 2024/02/20: In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMerck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period. This can primarily be attributed to a significant 50% rise in the company’s revenue ...

Merck (MRK) announced that it started the phase IIb/III BRUNELLO study on Restoret (MK-3000), a novel investigational Wnt agonist antibody, to treat diabetic macular edema (DME).This study will evaluate the safety and efficacy of two dose levels (high and low doses) of the drug compared with Roche’s (RHHBY) Lucentis (ranibizumab) in patients with DME.Restoret was added to Merck’s pipeline after it completed the acquisition of London-based private biotech EyeBio for around $1.3 billion in July. Following thi ...

Is the healthcare stock an underrated buy right now?Merck (MRK -0.67%) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500.Why isn't Merck's stock doing better in 2024?More importantly, could this healthcare company make for a good investment today?Merck is still heavily reliant on KeytrudaWhen a ph ...

Merck (MRK) announced that the European Commission has granted approval to a combination regimen of its blockbuster PD-L1 inhibitor, Keytruda, for expanded use in a type of bladder cancer. The approval is for Keytruda in combination with Astellas/Pfizer’s (PFE) antibody-drug conjugate Padcev for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma, a type of bladder cancer.The approval was expected as, in July, the Committee for Medicinal Products for Human Use of ...

JHVEPhotoMerck (NYSE:MRK) has been a strong performer within the Pharma space over the last several years, but is down this summer, following earnings and full-year profit guidance cut. Despite this, Merck remains one of the stronger performers among large healthcare equities, and is likely to return to all-time highs within the next several quarters, and potentially within 2024. There are multiple reasons for the reduced profit guidance, including the slowing growth seen by versions Gardasil, its Human ...

Merck (MRK) decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer, respectively.Merck took the decision based on the recommendations of an independent data monitoring committee (IDMC), which reviewed the interim data on both studies and concluded that the therapy’s risk/benefit profile did not support continuing either of the studies.Merck’s Lung Cancer Study Fails to Meet Goa ...

A month has gone by since the last earnings report for Merck (MRK) . Shares have added about 3.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Merck due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Q2 Earnings & Sales Beat Estimates, Guidance CutMerck’s second-qua ...